US Pharma MarketingTriveni Bio raises $65M ahead of upcoming readouts on eczema drugs
Triveni Bio closes a $65M Series C to fund two eczema drug candidates targeting kallikreins and IL-13, with Phase 2a data on lead asset TRIV-509 expected by year-end. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…
Triveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month.
The Series C was co-led by Ascenta Capital and Janus Henderson Investors and included Deep Track ...
Source: Endpoints News